2208
A liver biopsy in 2012 revealed marked fibrosis, leading the patient to start hepatitis C treatment with peginterferon alfa-2a, ribavirin and boceprevir.
 fibrosis, leading the patient: Subject; peginterferon alfa-2a, ribavirin and boceprevir: Treatment; fibrosis: Treatment.Disorder; peginterferon alfa-2a: Treatment.Drug; ribavirin: Treatment.Drug; boceprevir: Treatment.Drug; ribavirin: Combination.Drug; boceprevir: Combination.Drug; peginterferon alfa-2a: Combination.Drug
Given event type and trigger, please tell me the arguments of all the listed option. Output format is "name1: role1; name2: role2". 
Event type: potential therapeutic event 
  Option: Treatment.Freq, Subject.Population, Combination.Drug, Subject.Gender, Treatment.Duration, Subject, Effect, Treatment, Treatment.Disorder, Treatment.Time_elapsed, Subject.Disorder, Subject.Race, Treatment.Route, Treatment.Dosage, Subject.Age, Treatment.Drug 
Text: {0} 
Answer:
 fibrosis, leading the patient: Subject; peginterferon alfa-2a, ribavirin and boceprevir: Treatment; fibrosis: Treatment.Disorder; peginterferon alfa-2a: Treatment.Drug; ribavirin: Treatment.Drug; boceprevir: Treatment.Drug; ribavirin: Combination.Drug; boceprevir: Combination.Drug; peginterferon alfa-2a: Combination.Drug